Breaking News: Alentis Therapeutics Announces Exciting Phase 1 Results for Multiple Ascending Dose Study
The Future of Organ Fibrosis Treatment: A Breakthrough with ALE.F02 Introduction Alentis Therapeutics has recently announced promising results from the multiple-ascending dose (MAD) part of its Phase 1 clinical study of ALE.F02. This groundbreaking treatment targets Claudin-1 (CLDN1) and has shown a good safety profile, exposure, and target biological activity. The implications of these findings…